Palvella Therapeutics (PVLA) Operating Leases (2019 - 2026)

Palvella Therapeutics (PVLA) has 7 years of Operating Leases data on file, last reported at $375000.0 in Q1 2026.

• Quarterly Operating Leases changed N/A year-over-year to $375000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $375000.0 (changed N/A YoY) and the FY2025 annual result came in at $431000.0, changed N/A from the prior year.
• Operating Leases fell to $375000.0 in Q1 2026 per PVLA's latest filing, from $431000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $13.4 million in Q1 2022 and bottomed at $375000.0 in Q1 2026.
• The 4-year median for Operating Leases is $12.5 million (2022), against an average of $9.6 million.
• The widest annual swing landed in 2022, when Operating Leases fell 26.4%; it then declined 2.07% in 2023.
• Tracing PVLA's Operating Leases over 4 years: stood at $12.2 million in 2022, then rose by 4.76% to $12.8 million in 2023, then plunged by 96.64% to $431000.0 in 2025, then retreated by 12.99% to $375000.0 in 2026.
• Per Business Quant, the three latest PVLA Operating Leases figures stand at $375000.0 (Q1 2026), $431000.0 (Q4 2025), and $12.8 million (Q2 2023).

Peer Comparison